CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TheSlowLane who wrote (98)	3/16/1997 7:08:00 PM
From: Miljenko Zuanic	of 675

Paul, the competition issue is to complicate and unknown to be explain in short way. Sibia has unique screening technology (licensed from SALK Institute) and it screens library of small molecules (Lilly) and small peptides (exicitiory aminoacid , Ciba/Novartis) for CNS disorder. To my knowledge they didn't yet announced any promising molecules for Stroke/TBI. Sibia has patents covering small molecule for Parkinson's (they initiate PI)-specific ion channel receptor subtype is target. All this indicate ( accounting other companies who are developing drugs for CNS disorder) that it is very difficulty to develop specific agonist/antagonist for one (of many) subtype IC receptor in CNS. Also, they have not to interfere with other IC receptors in whole body. CNSI is now ahead from other developer, and (we all hope isn't it) with successful clinical trials enter in to market with Cerestat as first and only IC NMDA receptor antagonist. CNSI has patents covering library of small molecule as specific non-competitive NMDA antagonist, other IC receptor agonist/antagonist, and small peptides as neuron grow factors. Hope, this will help. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next